Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium

被引：25

作者：

Sola, Elsa ^{[1
,2
,3
]}

Pose, Elisa ^{[1
,2
,3
]}

Campion, Daniela ^{[4
]}

Piano, Salvatore ^{[5
]}

Roux, Olivier ^{[6
]}

Simon-Talero, Macarena ^{[7
]}

Uschner, Frank ^{[8
]}

de Wit, Koos ^{[9
]}

Zaccherini, Giacomo ^{[10
]}

Alessandria, Carlo ^{[4
]}

Beuers, Ulrich ^{[9
]}

Caraceni, Paolo ^{[10
]}

Francoz, Claire ^{[6
]}

Mookerjee, Rajeshwar P. ^{[11
]}

Trebicka, Jonel ^{[8
]}

Vargas, Victor ^{[7
]}

Serra, Miquel ^{[12
]}

Torres, Ferran ^{[13
]}

Montagnese, Sara ^{[14
]}

Krag, Aleksander ^{[15
,16
,17
]}

Hernaez, Ruben ^{[18
,19
,20
]}

Korenjak, Marko ^{[21
]}

Watson, Hugh ^{[22
,23
]}

Abraldes, Juan G. ^{[24
]}

Kamath, Patrick S. ^{[25
]}

Gines, Pere ^{[1
,2
,3
]}

机构：

[1] Hosp Clin Barcelona, Liver Unit, Villarroel 170, Barcelona 08036, Spain

[2] Univ Barcelona, Sch Med & Hlth Sci, Barcelona, Spain

[3] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain

[4] Univ Turin, Citta Salute & Sci Hosp, Div Gastroenterol & Hepatol, Turin, Italy

[5] Univ Padua, Dept Med DIMED, Unit Internal Med & Hepatol UIMH, Padua, Italy

[6] Hosp Beaujon, AP HP, Hepatol & Liver Intens Care Unit, Clichy, France

[7] Univ Autonoma Barcelona, Hosp Vall dHebron & Vall dHebron Res Unit VHIR, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Liver Unit, Barcelona, Spain

[8] Goethe Univ Frankfurt, Dept Internal Med 1, Frankfurt, Germany

[9] Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands

[10] Alma Mater Studiorum Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[11] UCL, Inst Liver & Digest Hlth, London, England

[12] Univ Pompeu Fabra, Ctr Res Hlth & Econ, Barcelona, Catalonia, Spain

[13] Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer, Biostat & Data Management Core Facil, Barcelona, Spain

[14] Univ Padua, Dept Med, Padua, Italy

[15] Odense Univ Hosp, Dept Gastroenterol & Hepatol, Odense, Denmark

[16] Odense Univ Hosp, Odense Patient Data Exploratory Network OPEN, Odense, Denmark

[17] Univ Southern Denmark, Inst Clin Res, Odense, Denmark

[18] Houston TX Ctr, Michael E DeBakey Vet Affairs Med Ctr, Sect Gastroenterol, Houston, TX USA

[19] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety IQuESt, Houston, TX USA

[20] Baylor Coll Med, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA

[21] European Liver Patients Assoc ELPA, Brussels, Belgium

[22] Evotec ID, Lyon, France

[23] Aarhus Univ, Dept Hepatol & Gastroenterol, Aarhus, Denmark

[24] Univ Alberta, Div Gastroenterol, CEGIIR, Cirrhosis Care Clin,Liver Unit, Edmonton, AB, Canada

[25] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA

来源：

JOURNAL OF HEPATOLOGY | 2021年 / 74卷 / 01期

关键词：

Cirrhosis; Liver transplant; Clinical trials; Endpoints; Ascites; AKI; Hepatic encephalopathy; Hyponatremia; Infections; ACLF; Quality of life; QUALITY-OF-LIFE; SPONTANEOUS BACTERIAL PERITONITIS; V-2 RECEPTOR ANTAGONIST; LONG-TERM PROGNOSIS; INTRAHEPATIC PORTOSYSTEMIC SHUNTS; GELATINASE-ASSOCIATED LIPOCALIN; SERUM SODIUM CONCENTRATION; PARACENTESIS PLUS ALBUMIN; URINARY ETHYL GLUCURONIDE; ACUTE KIDNEY INJURY;

D O I：

10.1016/j.jhep.2020.08.009

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Management of decompensated cirrhosis is currently geared towards the treatment of complications once they occur. To date there is no established disease-modifying therapy aimed at halting progression of the disease and preventing the development of complications in patients with decompensated cirrhosis. The design of clinical trials to investigate new therapies for patients with decompensated cirrhosis is complex. The population of patients with decompensated cirrhosis is heterogeneous (i.e., different etiologies, comorbidities and disease severity), leading to the inclusion of diverse populations in clinical trials. In addition, primary endpoints selected for trials that include patients with decompensated cirrhosis are not homogeneous and at times may not be appropriate. This leads to difficulties in comparing results obtained from different trials. Against this background, the LiverHope Consortium organized a meeting of experts, the goal of which was to develop recommendations for the design of clinical trials and to define appropriate endpoints, both for trials aimed at modifying the natural history and preventing progression of decompensated cirrhosis, as well as for trials aimed at managing the individual complications of cirrhosis. (C) 2020 European Association for the Study of the Liver. Published by Elsevier B.V.

引用

页码：200 / 219

页数：20

共 50 条

[31] Introduction to improving clinical trials: Contemporary design solutions including endpoints, surrogate comparators, project planning, and computer-assisted trial design (CATD)
Olson, CM
Shapiro, D
DRUG INFORMATION JOURNAL, 1998, 32 (04): : 955 - 956
[32] Introduction to Improving Clinical Trials: Contemporary Design Solutions Including Endpoints, Surrogate Comparators, Project Planning, and Computer-Assisted Trial Design (CATD)
Camilla M. Olson
David Shapiro
Drug information journal : DIJ / Drug Information Association, 1998, 32 : 955 - 956
[33] Design and reporting characteristics of clinical trials investigating sedation practices in the paediatric intensive care unit: a scoping review by SCEPTER (Sedation Consortium on Endpoints and Procedures for Treatment, Education and Research)
Lee, Jennifer Jooyoung
Price, Jerri C.
Gewandter, Jennifer
Kleykamp, Bethea A.
Biagas, Katherine, V
Naim, Maryam Y.
Ward, Denham
Dworkin, Robert H.
Sun, Lena S.
BMJ OPEN, 2021, 11 (10):
[34] Toward a Generalized Framework of Core Measurement Areas in Clinical Trials: A Position Paper for OMERACT 11
Boers, Maarten
Idzerda, Leanne
Kirwan, John R.
Beaton, Dorcas
Escorpizo, Reuben
Boonen, Annelies
Magasi, Susan
Sinha, Ian
Stucki, Gerold
Tugwell, Peter
JOURNAL OF RHEUMATOLOGY, 2014, 41 (05) : 978 - 985
[35] Complexity of design in early phase respiratory clinical trials; evaluating impact of primary endpoints and sponsor size
Marco-Arino, Nicolas
Jauhiainen, Alexandra
Betts, Joanne
Da Silva, Carla A.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2021, 22
[36] Choice of novel endpoints in clinical trials evaluating the efficiency of drug therapy in patients with pulmonary hypertension
Avdeev, S. N.
TERAPEVTICHESKII ARKHIV, 2014, 86 (03) : 88 - 93
[37] Doubly adaptive biased coin design to improve Bayesian clinical trials with time-to-event endpoints
Cao, Wenhao
Zhu, Hongjian
Wang, Li
Zhang, Lixin
Yu, Jun
STATISTICS IN MEDICINE, 2024, 43 (09) : 1743 - 1758
[38] Considerations for Selecting Cognitive Endpoints and Psychological Patient-Reported Outcomes for Clinical Trials in Pediatric Patients With Sickle Cell Disease
Hood, Anna M.
Crosby, Lori E.
Stotesbury, Hanne
Kolbel, Melanie
Kirkham, Fenella J.
FRONTIERS IN NEUROLOGY, 2022, 13
[39] AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: a 2020 update
Caraceni, Paolo
Angeli, Paolo
Prati, Daniele
Bernardi, Mauro
Berti, Pierluigi
Bennardello, Francesco
Fiorin, Francesco
Piccoli, Pierluigi
BLOOD TRANSFUSION, 2021, 19 (01) : 9 - 13
[40] Unlocking the DOORdhow to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials
Ong, Sean W. X.
Petersiel, Neta
Loewenthal, Mark R.
Daneman, Nick
Tong, Steven Y. C.
Davis, Joshua S.
CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (08) : 1024 - 1030

← 1 2 3 4 5 →